Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-national, Multi-center, Randomized, Double-Blind, Active-Controlled, Phase III Study to Investigate the Efficacy and Safety of 'GC3107(BCG Vaccine)' After Intradermal Administration in Healthy Infants

NCT03947138 is registered in ClinicalTrials.gov with Green Cross Corporation as lead sponsor.

NCT NCT03947138
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03947138 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-national, Multi-center, Randomized, Double-Blind, Active-Controlled, Phase III Study to Investigate the Efficacy and Safety of 'GC3107(BCG Vaccine)' After Intradermal Administration in Healthy Infants
Lead sponsor
Green Cross Corporation
Phase
Phase 3
Overall status
Completed
Start date
August 6, 2019
Completion date
September 6, 2022
Enrollment
750 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

bcg vaccination reaction, tuberculosis